查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球子宫肌瘤治疗市场-2022-2029
市场调查报告书
商品编码
1143403

全球子宫肌瘤治疗市场-2022-2029

Global Uterine Fibroids Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

预计 2021 年子宫肌瘤治疗市场价值 12.802 亿美元，在 2022-2029 年的预测期内达到 9.4% 的复合年增长率 (CAGR)。

子宫肌瘤是女性子宫最常见的良性、非癌性肿瘤，在分娩时常见。肌瘤仅在出现症状时才进行治疗，治疗范围从药物治疗到侵入性手术。子宫肌瘤治疗市场具有显着的增长机会。全球子宫肌瘤治疗市场的主要驱动力是由于女性老年人口的增加、荷尔蒙失调的流行和生活方式的改变，患者人数不断增加。

市场动态

全球肌瘤治疗市场的主要增长因素是个人对疾病的认识提高、高效和新技术的发展、全球政府活动的增加、肌瘤发病率的激增以及人们生活方式的改变。育龄妇女人数增加。

子宫肌瘤发病率的上升推动了全球市场的增长。

子宫肌瘤是女性最常见的盆腔肿瘤，全球发病率为 21.4%。子宫平滑肌瘤是女性最常见和研究不足的疾病之一。通常被称为子宫肌瘤，这些肿瘤，通常被称为子宫肌瘤，主要发生在生育期的女性中，并且在高达 70% 的白人女性和超过 80% 的非洲裔女性的一生中被诊断出来，根据以国际妇产科联合会2020年数据为准。这种疾病正在对世界各地的医疗保健服务和医疗保健成本产生重大影响。大多数患有子宫肌瘤的女性是无症状的，但大约30%的女性会出现异常子宫出血、贫血、盆腔疼痛或压迫感、背痛、尿频、便秘和不孕等严重症状，需要干预增加。美国每年约有 650 万女性接受肌瘤治疗，约三分之一 (28%) 的工作患者报告因肌瘤症状而缺工。

对治疗方案缺乏认识将阻碍市场增长。

但是，社区和医学界对子宫肌瘤的关注有限，这使高危女性无法获得所需的有关该疾病的知识。 《女性健康杂誌》2020 年的一项研究发现，只有 49% 的有肌瘤症状的女性在没有临床诊断肌瘤的情况下处于危险之中。症状出现后，这些女性中的大多数（60%）试图自己控制症状或等待症状消退（50%）。即使诊断为肌瘤，治疗选择也很有限，并且会影响生育能力。女性可以服用非处方非甾体抗炎药 (NSAID) 和对乙□氨基酚来减轻与子宫肌瘤相关的疼痛，但这些只是治疗盆腔疼痛的临时方法。一些避孕药可以帮助缓解大出血，但它们并不适用于所有女性，也不是试图怀孕的女性的选择。

COVID-19 影响分析

COVID-19 大流行对妇科手术产生了重大影响。美国外科学院建议在 2020 年 3 月之前推迟所有非必要的侵入性手术。根据 2021 年 12 月发表的题为《主要大学医院对 COVID-19 妇科手术的反应及影响分析》的研究论文，2019 年进行了 1,545 例妇科手术。相比之下，2020 年将有 942 例，减少 39.0%。它对世界市场产生了负面影响。

细分分析

预计在预测期内（2022-2029 年），子宫肌瘤治疗市场将更好地掌握手术方法细分市场。

手术方法部分将在 2021 年拥有最大的市场份额。如果症状轻微，药物治疗是有效的。然而，医生通常建议对子宫肌瘤引起中度或重度症状（如疼痛和大出血）的女性进行治疗。治疗子宫肌瘤的手术包括器官保留手术和切除部分或全部器官。子宫肌瘤的手术治疗使用三种方法（腹腔镜、腹腔镜、阴道）或三种方法的组合。几种类型的手术用于治疗肌瘤。这些包括子宫内膜消融术、MRI 引导手术、子宫切除术、子宫动脉栓塞术 (UAE) 和射频消融术。其中，子宫切除术将在 2021 年占据最大的市场份额。

按地区分析

全球子宫肌瘤治疗市场预计将由北美主导。

北美在子宫肌瘤治疗市场占据主导地位，预计在预测期间（2022-2029 年）将呈现类似趋势。尤其是在医疗保健行业成熟的美国和加拿大，提高意识和轻鬆获得先进技术是促成因素。越来越多的患有激素紊乱的患者和子宫癌的患病率上升是该地区子宫肌瘤治疗市场的主要增长动力。例如，在美国，子宫肌瘤的患病率在 35 岁时为 60%，到 50 岁时上升到 80% 以上。

此外，开放手术的微创和有效替代方案的出现、技术进步、治疗类型的频繁创新，以及监管部门批准的增加和有利的报销政策正在推动该地区的市场。预计将支持增长的

波士顿科学公司

概述

成立于 1979 年。总部设在美国。开发、製造和销售微创医疗设备。我们的治疗类型用于介入心脏病学、心律管理、外周介入、电生理学、神经血管介入、内窥镜检查、泌尿科、妇科和神经调节。

治疗类型组合

Symphion 组织去除系统。 一体式 Symphon 系统旨在彻底改变切除子宫组织的方式。它整合和协调突破性液体管理、直接宫内压力监测和无刀切除。

全球子宫肌瘤治疗报告将提供对大约 40 多个市场数据表、45 多个 数字和 200 多页（大约）的访问。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 子宫肌瘤发病率增加
      • 技术进步的增加
    • 约束因素
      • 与手术治疗相关的并发症
    • 商机
    • 影响分析

第5章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 流行病学
  • 定价分析
  • 比较分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按治疗类型

  • 非激素治疗非甾体抗炎药 (NSAID)
  • 激素类药物
    • 口服避孕药
    • 黄体酮/抗肥胖药
    • GnRH 激动剂
  • 手术方式
    • 子宫内膜切除术
    • MRI 引导的手术
    • 子宫切除术
    • 子宫肌瘤摘除术
    • 子宫动脉栓塞术
    • 射频消融

第 8 章按类型

  • 粘膜下层
  • 粘膜下层
  • 胸腔内
  • 学究气

第 9 章，最终用户

  • 医院和诊所
  • 升序
  • 伤口治疗中心
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准

第 12 章公司简介

  • 波士顿科学公司（Minerva Surgical）
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Cooper Surgical, Inc.
  • Olympus Corporation
  • Acessa Health（Halt Medical, Inc.）
  • Gynesonics
  • Conmed Corporation
  • AbbVie Inc.
  • Medtronic
  • Karl Storz
  • Richard Wolf GmbH
  • LiNA Medical USA
  • Blue Endo（*LIST NOT EXHAUSTIVE）

第13章 DataM

简介目录
Product Code: DMPH8

Market Overview

Uterine Fibroids Treatment Market size was valued at USD 1,280.20 million in 2021 and is estimated to reach a compound annual growth rate (CAGR) of 9.4% over the forecast period 2022 to 2029.

Uterine fibroids are a woman's uterus's most commonly benign, non-cancerous tumors, often seen during childbearing. Fibroids are only treated if they cause symptoms, and treatment options range from medications to invasive surgery. The uterine fibroids treatment market has significant opportunities to grow. The global uterine fibroids treatment market is primarily driven by an increasing patient pool owing to the increasing female geriatric population, the growing prevalence of hormonal disorders, and changing lifestyles.

Market Dynamics

Major growth drivers of the uterine fibroids treatment market over the globe are an increase in consciousness among individuals about diseases, growth of efficient and new technology, rising government activities over the globe, a surge in occurrence of uterine fibroids, and changed people's lifestyle, and increasing number of women of reproductive age.

The rising incidences of uterine fibroids drive global market growth.

Uterine fibroids are women's most common pelvic tumors, occurring globally, with a prevalence of 21.4%. Uterine leiomyomas are among women's most common yet understudied diseases. The International Federation of Gynecology and Obstetrics 2020 data states that these tumors, commonly known as fibroids, affect women mainly during their reproductive years and are diagnosed in up to 70% of white women and more than 80% of women of African ancestry during their lifetime. This disease has a profound impact on health care delivery and costs worldwide. Though most women with fibroids are asymptomatic, approximately 30% will present with severe symptoms, including abnormal uterine bleeding, anemia, pelvic pain and pressure, back pain, urinary frequency, constipation, or infertility, and will require intervention. Every year in the United States, approximately 6.5 million women seek treatment for fibroids, and nearly 1/3 of employed patients (28%) report missing work days due to fibroid symptoms.

The low awareness of treatment options will hamper the growth of the market.

However, limited attention to fibroids in the community and the medical society means that at-risk women do not have access to the knowledge they need regarding the disease. The 2020 study in the Journal of Women's Health uncovered that only 49% of at-risk women with manifestations suggest fibroids but not a clinical diagnosis of uterine fibroids. Following the onset of their symptoms, most of these women (60%) tried to manage symptoms themselves or waited to see if the symptoms went away (50%). Even when women receive a fibroid diagnosis, their treatment options are limited and affect their fertility. Women can take over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen to alleviate pain associated with uterine fibroids, but these are just momentary fixes for pelvic pain. Some forms of birth control can help alleviate heavy bleeding but don't work for all women and are not an option for women trying to get pregnant.

COVID-19 Impact Analysis

The COVID-19 pandemic had a significant impact on gynecological surgery. The American College of Surgeons has recommended delaying all unnecessary invasive surgery by March 2020. According to a December 2021 research paper titled analysis of response and effects impact of COVID-19 on gynecological surgery in major university hospitals, 1,545 gynecologic cases were done in 2019, compared to 942 cases in 2020, suggesting a 39.0% decline. Negatively impacting the global market.

Segment Analysis

The surgical methods segment is expected to have a greater grasp of the uterine fibroids treatment market during the forecast period (2022-2029).

The surgical methods segment accounts for the largest market share in 2021. Medications can help if the symptoms are mild. However, doctors usually recommend procedures for women whose fibroids cause moderate or severe symptoms, like pain or heavy bleeding. Surgery to treat uterine fibroids can include organ preservation or involve partial or total organ removal. Three approaches (abdominal, laparoscopic, vaginal) or a combination of the three are used for the surgical treatment of uterine fibroids. Several types of surgical procedures are performed for the treatment of uterine fibroids. Dome of them includes endometrial Ablation, MRI Guided Procedures, Hysterectomy, Myomectomy, Uterine Artery Embolization (UAE), and Radiofrequency Ablation, among others. Among these, Hysterectomy accounted for the largest market share in 2021.

Geographical Analysis

North America is expected to dominate the global uterine fibroids treatment market.

North America dominates the market for uterine fibroids treatment and is expected to show a similar trend over the forecast period (2022-2029). Owing to its established healthcare industry, particularly in the U.S. and Canada, increased awareness, and easy accessibility to advanced technologies. The increased patient pool undergoing hormonal disorders and increasing prevalence of uterine cancer is the key growth driving factor for this regional uterine fibroid treatment market. For instance, in the USA, the prevalence of uterine fibroids was 60% at age 35, which increased to more than 80% by 50 years among women.

Moreover, the advent of minimally invasive and effective alternatives to open surgeries, technological advancements, and frequent Treatment Type innovations coupled with an increase in regulatory approvals and favorable reimbursement policies are expected to boost the market's growth in the region.

Competitive Landscape

The uterine fibroids treatment market is a moderately competitive presence of local and global companies. Some of the key players which are contributing to the growth of the market are Boston Scientific Corporation (Minerva Surgical), Cooper Surgical, Inc., Olympus Corporation, Acessa Health (Halt Medical, Inc.), Gynesonics, Conmed Corporation, AbbVie Inc., Medtronic, Karl Storz, Richard Wolf GmbH, LiNA Medical USA, Blue Endo among others. The major players are adopting several growth strategies, such as Treatment Type launches, acquisitions, and collaborations, contributing to the global market growth. For instance, in May 12, 2020, Minerva Surgical, Inc, acquired the following Intrauterine Health Treatment Types from Boston Scientific: the Symphion Tissue Removal System; the Resectr Tissue Resection Device; and the Genesys HTA System.

Boston Scientific Corporation

Overview:

The company was founded in 1979. It has headquarters in the United States. Boston Scientific Corporation develops, manufactures, and markets minimally invasive medical devices. The Company's Treatment Types are used in interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, endoscopy, urology, gynecology, and neuromodulation.

Treatment Type Portfolio:

Symphion Tissue Removal System: The all-in-one Symphion System is designed to transform how you remove uterine tissue. It unites breakthrough fluid management, direct intrauterine pressure monitoring, and bladeless resection to work together perfectly.

The global uterine fibroids treatment report would provide access to approximately 40+ market data tables, 45+ figures, and in the range of 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Incidences of Uterine Fibroids
      • 4.1.1.2. Increasing Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with Surgical Treatments
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Epidemiology
  • 5.5. Pricing Analysis
  • 5.6. Comparative analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
    • 7.1.2. Market Attractiveness Index, By Treatment Type Segment
  • 7.2. Non-hormonal Treatment: Non-steroidal Anti-inflammatory Agents (NSAIDs)
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Hormonal Treatment
    • 7.3.1. Oral contraceptives
    • 7.3.2. Progestins/Antiprogestins
    • 7.3.3. GnRH Agonists
  • 7.4. Surgical Methods
    • 7.4.1. Endometrial Ablation
    • 7.4.2. MRI Guided Procedures
    • 7.4.3. Hysterectomy
    • 7.4.4. Myomectomy
    • 7.4.5. Uterine Artery Embolization
    • 7.4.6. Radiofrequency Ablation

8. By Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type Segment
    • 8.1.2. Market Attractiveness Index, By Type Segment
  • 8.2. Submucosal
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subserosal
  • 8.4. Intramural
  • 8.5. Pedunculated

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User Segment
    • 9.1.2. Market Attractiveness Index, By End User Segment
  • 9.2. Hospitals And Clinics
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. ASCs
  • 9.4. Wound Care Centers
  • 9.5. Other

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2021-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking

12. Company Profiles

  • 12.1. Boston Scientific Corporation (Minerva Surgical)
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cooper Surgical, Inc.
  • 12.3. Olympus Corporation
  • 12.4. Acessa Health (Halt Medical, Inc.)
  • 12.5. Gynesonics
  • 12.6. Conmed Corporation
  • 12.7. AbbVie Inc.
  • 12.8. Medtronic
  • 12.9. Karl Storz
  • 12.10. Richard Wolf GmbH
  • 12.11. LiNA Medical USA
  • 12.12. Blue Endo(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us